Nebulizers and Vaporizers

"Nebulizers and Vaporizers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments.

Descriptor ID	D009330
MeSH Number(s)	E07.605
Concept/Terms	Nebulizers and Vaporizers Nebulizers and Vaporizers Vaporizers and Nebulizers Vaporizers Vaporizers Vaporizer Inhalers Inhalers Inhaler Inhalators Inhalator Nebulizers Nebulizers Nebulizer Atomizers Atomizers Atomizer Inhalation Devices Inhalation Devices Device, Inhalation Devices, Inhalation Inhalation Device

Below are MeSH descriptors whose meaning is more general than "Nebulizers and Vaporizers".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Equipment and Supplies [E07]
Nebulizers and Vaporizers [E07.605]

Below are MeSH descriptors whose meaning is related to "Nebulizers and Vaporizers".

Below are MeSH descriptors whose meaning is more specific than "Nebulizers and Vaporizers".

Nebulizers and Vaporizers
Dry Powder Inhalers
Metered Dose Inhalers

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Nebulizers and Vaporizers" by people in this website by year, and whether "Nebulizers and Vaporizers" was a major or minor topic of these publications.

Bar chart showing 26 publications over 15 distinct years, with a maximum of 7 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
2001	1	0	1
2006	0	1	1
2008	0	2	2
2009	0	1	1
2010	0	2	2
2012	0	2	2
2013	1	0	1
2016	1	0	1
2018	2	1	3
2019	0	1	1
2020	2	5	7
2021	0	1	1
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Nebulizers and Vaporizers" by people in Profiles.

Radu S, Zarinafsar S, Ryan GW, Chainani S, Becker S, Arenas J, Spano MA, Shillan HN, Hoque S, Sadasivam R, Pbert L, Luther J, Trivedi MK. Participant Perspectives on the Implementation of a School-Linked Text-Message Intervention to Improve Pediatric Asthma Medication Adherence. Pediatr Allergy Immunol Pulmonol. 2024 03; 37(1):13-21.

View in: PubMed
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS. Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. Int J Chron Obstruct Pulmon Dis. 2022; 17:1633-1642.

View in: PubMed
Chipps BE, Murphy KR, Oppenheimer J. 2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges. J Allergy Clin Immunol Pract. 2022 01; 10(1S):S19-S30.

View in: PubMed
Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Jones CE, Kilbride S, LaFon D, Lipson DA, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Lange P. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Ann Am Thorac Soc. 2021 05; 18(5):788-798.

View in: PubMed
Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 03; 159(3):985-995.

View in: PubMed
Stefan MS, Fisher KA, Lindenauer PK. Does Adherence to GOLD Recommendations Regarding Inhaler Therapy Lead to Better Patient Outcomes?: Insights from the LOTT Trial. Chest. 2020 08; 158(2):437-439.

View in: PubMed
Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC, Lipson DA. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Adv Ther. 2020 09; 37(9):3775-3790.

View in: PubMed
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020 Jun 05; 21(1):139.

View in: PubMed
Halpin DMG, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, Singh D, Wise R, Criner GJ. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020 05; 55(5).

View in: PubMed
Keller T, Spece LJ, Donovan LM, Udris E, Coggeshall SS, Griffith M, Bryant AD, Casaburi R, Cooper JA, Criner GJ, Diaz PT, Fuhlbrigge AL, Gay SE, Kanner RE, Martinez FJ, Panos RJ, Shade D, Sternberg A, Stibolt T, Stoller JK, Tonascia J, Wise R, Yusen RD, Au DH, Feemster LC. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial. Chest. 2020 08; 158(2):529-538.

View in: PubMed

People

Explore

Similar Concepts

Top Journals